Methotrexate analogues display enhanced inhibition of TNF-α production in whole blood from RA patients

Scandinavian Journal of Rheumatology

Volumn 43, Issue 1, 2014, Pages 9-16

  Van Der Heijden, J W ^a   Assaraf, Y G ^b   Gerards, A H ^c   Oerlemans, R ^a   Lems, W F ^a   Scheper, R J ^a   Dijkmans, B A C ^a   Jansen, G ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c Schiedam   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BGC 9331; CD3 ANTIBODY; FOLIC ACID ANTAGONIST; GW 1843; METHOTREXATE; MONOCLONAL ANTIBODY CD28; PELITREXOL; PEMETREXED; PT 644; RALTITREXED; TALOTREXIN; TRIMETREXATE; TRIMETREXATE GLUCURONATE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BLOOD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; MALE; MIDDLE AGED; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; FOLIC ACID ANTAGONISTS; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; ORNITHINE; PTERINS; QUINAZOLINES; T-LYMPHOCYTES; THIOPHENES; TRIMETREXATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84893011705     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2013.797490     Document Type: Article

References (50)

1. Bertino Jr. Karnofsky memorial lecture. Ode to methotrexate. J Clin Oncol 1993;11:5-14.
2. Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum 2004;50:1370-82. (Pubitemid 38608058)
3. Peters GJ, Jansen G. Antimetabolites. In: Souhami RL, Tannock I, Hohenberger PHJC, editors. Oxford textbook of oncology. Oxford: Oxford University Press, 2001:663-713.
4. Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH. Antiinflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 2001;60:729-35. (Pubitemid 32685871)
5. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005;57:163-72. (Pubitemid 41043882)
6. Genestier L, Paillot R, Quemeneur L, Izeradjene K, Revillard JP. Mechanisms of action of methotrexate. Immunopharmacology 2000;47:247-57. (Pubitemid 30394541)
7. Swierkot J, Szechinski J. Methotrexate in rheumatoid arthritis. Pharmacol Rep 2006;58:473-92. (Pubitemid 44383273)
8. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993;92:2675-82. (Pubitemid 24006532)
9. Riksen NP, Barrera P, van den Broek PH, van Riel PL, Smits P, Rongen GA. Methotrexate modulates the kinetics of adenosine in humans in vivo. Ann Rheum Dis 2006;65:465-70.
10. Fairbanks LD, RuckemannK,Qiu Y, Hawrylowicz CM, Richards DF, Swaminathan R, et al. Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis? Biochem J 1999;342:143-52. (Pubitemid 29410860)
11. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998;102:322-8. (Pubitemid 28335191)
12. Herman S, Zurgil N, Deutsch M. Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines. Inflamm Res 2005;54:273-80. (Pubitemid 41185488)
13. Phillips DC, Woollard KJ, Griffiths HR. The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species. Br J Pharmacol 2003;138:501-11. (Pubitemid 36269490)
14. Spurlock CF 3rd, Tossberg JT, Fuchs HA, Olsen NJ, Aune TM. Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. Arthritis Rheum 2012;64:1780-9.
15. Winter-Vann AM, Kamen BA, Bergo MO, Young SG, Melnyk S, James SJ, et al. Targeting Ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate. Proc Natl Acad Sci USA 2003;100:6529-34. (Pubitemid 36666615)
16. Majumdar S, Aggarwal BB. Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation. J Immunol 2001;167:2911-20. (Pubitemid 32768926)
17. Wolfe F. The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol 1995;9:619-32.
18. van der Heijden JW, Dijkmans BA, Scheper RJ, Jansen G. Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs - from bench to bedside. Nat Clin Pract Rheumatol 2007;3:26-34.
19. Gonen N, Assaraf YG. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat 2012;15:183-210.
20. Rots MG, Pieters R, Kaspers GJ, Veerman AJ, Peters GJ, Jansen G. Classification of ex vivo methotrexate resistance in acute lymphoblastic and myeloid leukaemia. Br J Haematol 2000;110:791-800.
21. Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D, Bertino Jr. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 1996;335:1041-8. (Pubitemid 26338736)
22. Jansen G, Mauritz R, Drori S, Sprecher H, Kathmann I, Bunni M, et al. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem 1998;273:30189-98. (Pubitemid 28545482)
23. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 1999;59:2532-5. (Pubitemid 29269093)
24. Peters GJ, Jansen G. Folate homeostasis and antiproliferative activity of folates and antifolates. Nutrition 2001;17:737-8. (Pubitemid 32816324)
25. Walling J. From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs 2006;24:37-77. (Pubitemid 43168187)
26. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, et al. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 1991;51:5579-86.
27. Rhee MS, Galivan J, Wright JE, Rosowsky A. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells. Mol Pharmacol 1994;45:783-91. (Pubitemid 24139209)
28. Rosowsky A, Wright JE, Vaidya CM, Bader H, Forsch RA, Mota CE, et al. Synthesis and potent antifolate activity and cytotoxicity of B-ring deaza analogues of the nonpolyglutamatable dihydrofolate reductase inhibitor Nalpha-(4-amino-4-deoxypteroyl)-Ndeltahemiphthaloyl- L-ornithine (PT523). J Med Chem 1998;41: 5310-19. (Pubitemid 29016322)
29. Duch DS, Banks S, Dev IK, Dickerson SH, Ferone R, Heath LS, et al. Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase. Cancer Res 1993;53:810-18. (Pubitemid 23077867)
30. Jackman AL, Kimbell R, Aherne GW, Brunton L, Jansen G, Stephens TC, et al. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase. Clin Cancer Res 1997;3:911-21. (Pubitemid 27252939)
31. Boritzki TJ, Barlett CA, Zhang C, Howland EF. AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase. Invest New Drugs 1996;14:295-303. (Pubitemid 26383944)
32. Gerards AH, de Lathouder S, de Groot ER, Dijkmans BA, Aarden LA. Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford) 2003;42:1189-96. (Pubitemid 37258482)
33. Swierkot J, Miedzybrodzki R, Szymaniec S, Szechinski J. Activation dependent apoptosis of peripheral blood mononuclear cells from patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 2004;63:599-600. (Pubitemid 38530209)
34. Spurlock CF 3rd, Aune ZT, Tossberg JT, Collins PL, Aune JP, Huston JW 3rd, et al. Increased sensitivity to apoptosis induced by methotrexate is mediated by JNK. Arthritis Rheum 2011;63: 2606-16.
35. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-19.
36. Westerhof GR, Schornagel JH, Kathmann I, Jackman AL, Rosowsky A, Forsch RA, et al. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular structure and biological activity. Mol Pharmacol 1995;48:459-71.
37. Blits M, Jansen G, Vosslamber S, Assaraf YG, Verweij CL. Regulation of folate pathway related genes in methotrexate naïve and methotrexate treated patients with rheumatoid arthritis. Arthritis Rheum 2012;64:S911, meeting abstract 2154.
38. Jansen G, Barr H, Kathmann I, Bunni MA, Priest DG, Noordhuis P, et al. Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestration. Mol Pharmacol 1999;55:761-9. (Pubitemid 29165442)
39. Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford) 2004;43:267-71. (Pubitemid 38313172)
40. Arabelovic S, Sam G, Dallal GE, Jacques PF, Selhub J, Rosenberg IH, et al. Preliminary evidence shows that folic acid fortification of the food supply is associated with higher methotrexate dosing in patients with rheumatoid arthritis. J Am Coll Nutr 2007;26:453-5. (Pubitemid 47512041)
41. Zhao R, Gao F, Goldman ID. Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochem Pharmacol 2001;61:857-65. (Pubitemid 32245569)
42. Rots MG, Pieters R, Kaspers GJ, van Zantwijk CH, Noordhuis P, Mauritz R, et al. Differential methotrexate resistance in childhood T- versus common/preB-acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay. Blood 1999;93:1067-74. (Pubitemid 29067873)
43. Qiu A, JansenM, Sakaris A, Min SH, Chattopadhyay S, Tsai E, et al. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 2006;127:917-28. (Pubitemid 44792250)
44. Zhao R, Matherly LH, Goldman ID. Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Rev Mol Med 2009;11:e4.
45. Desmoulin SK, Wang Y, Wu J, Stout M, Hou Z, Fulterer A, et al. Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors. Mol Pharmacol 2010;78:577-87.
46. van der Heijden JW, Oerlemans R, Dijkmans BA, Qi H, van der Laken CJ, Lems WF, et al. Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum 2009;60:12-21.
47. van der Heijden JW, Oerlemans R, Tak PP, Assaraf YG, Kraan MC, Scheffer GL, et al. Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide. Arthritis Rheum 2009;60:669-77.
48. Nakashima-Matsushita N, Homma T, Yu S,Matsuda T, Sunahara N, Nakamura T, et al. Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patientswith rheumatoid arthritis.ArthritisRheum1999;42:1609-16. (Pubitemid 30263627)
49. Montesinos MC, Desai A, Delano D, Chen JF, Fink JS, Jacobson MA, et al. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 2003;48:240-7. (Pubitemid 36091669)
50. Castaneda O, Nair MG. Controlled trial of methotrexate versus CH- 1504 in the treatment of rheumatoid arthritis. J Rheumatol 2006;33:862-4.